Cochlear Limited has achieved a significant milestone with the FDA approval of its Cochlear™ Nucleus® Nexa™ System, marking the launch of the world’s first smart cochlear implant system. At the core of this innovation is a firmware-upgradeable implant—a major leap forward in hearing technology that enables recipients to access future innovations through both their implant and sound processor. Unlike traditional systems that rely solely on external upgrades, the Nexa Implant is the first to run its own firmware, featuring a new, high-performance chipset with onboard diagnostics, internal memory, and the capacity to adapt over time—delivering on the promise of truly future-ready hearing care.

In everyday use, the Nucleus Nexa System offers patients an intuitive and streamlined experience. The Dynamic Power Management algorithm enables the system to intelligently respond to the user’s environment and listening needs, while maximizing battery efficiency throughout the day. The system includes two sound processor options—the Nucleus 8 Nexa Sound Processor and the Kanso 3 Nexa Sound Processor—both of which are smaller, lighter, and more efficient than their predecessors, delivering a discreet, all-day hearing solution. The implant’s internal memory stores personalized hearing settings (MAPs), ensuring seamless connectivity and continued function even in the event of a lost or damaged sound processor.

With over 430 million people worldwide affected by disabling hearing loss, the Nucleus Nexa System represents a bold step forward in improving access, reliability, and outcomes in hearing health. By combining cutting-edge smart features with a connected care ecosystem—including the Nucleus Smart App, SmartNav tools, and wireless accessories—Cochlear is not only enhancing hearing performance but also reducing the burden on caregivers and clinicians. This groundbreaking system redefines what's possible in cochlear implantation and sets a new industry standard for delivering personalized, durable, and future-ready hearing care.